7 completed, 6 recruiting, 4 terminated, 3 not yet recruiting. 15 Phase 1, 8 Phase 2, 2 Early Phase 1, 2 Not applicable, 1 Phase 3.
Follow B-cell Malignancies: new trials by email Literature Review of B-cell Malignancies trials Research Report on B-cell Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0920 - Diffuse Large B-Cell Lymphoma, B-cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-12-11 | 2026-10-21 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0050 - Diffuse Large B-Cell Lymphoma, B-Cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-11-30 | 2026-10-19 |
| Expression of CD274 (PD-L1) and CD276 in B-cell Malignancies: A Study by Flowcytometry B-cell Malignancies | Not yet recruiting | Assiut University | 159 | 2026-07-01 | 2026-04-07 | |
| A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies Emavusertib, Zanubrutinib - Chronic Lymphocytic Leukemia, B-cell Malignancies | Phase 2 | Recruiting | Curis, Inc. | 108 | 2026-04-23 | 2026-06-12 |
| Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies in vivo CAR-T drug based on LNP-mRNA - B-cell Malignancies | Early Phase 1 | Recruiting | Xinqiao Hospital of Chongqing | 47 | 2025-12-20 | 2026-01-20 |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-10-30 |
| JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies JY231 Injection - B-cell Malignancies | Not applicable | Recruiting | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 36 | 2025-07-01 | 2025-07-15 |
| A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies Therapeutic 4SCAR19 cells - B-cell Malignancies | Not applicable | Terminated | Shenzhen Geno-Immune Medical Institute | 200 | 2025-05-01 | 2026-10-30 |
| Evaluation of SYS6005 in Patients With Advanced Malignant Tumor SYS6005 - B-cell Malignancies, Solid Tumors | Phase 1 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 132 | 2025-04-03 | 2025-05-14 |
| A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. AZD5492 - B-cell Malignancies | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 174 | 2024-09-18 | 2026-09-30 |
| A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies TT-01488 Tablets - B-Cell Malignancies | Phase 1 | Recruiting | TransThera Sciences (Nanjing), Inc. | 37 | 2023-03-30 | 2023-11-21 |
| Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies TT-01488 - B-Cell Malignancies | Phase 1 | Unknown | TransThera Sciences (Nanjing), Inc. | 37 | 2022-06-01 | 2022-06-09 |
| Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Zanubrutinib, Fluconazole, Diltiazem - B-cell Malignancies | Phase 1 | Completed | BeiGene | 26 | 2020-11-15 | 2024-10-26 |
| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib - B-Cell Malignancies | Phase 2 | Active not recruiting | Incyte Corporation | 112 | 2020-08-03 | 2026-06-25 |
| A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib Zanubrutinib, Tislelizumab - B-cell Malignancies | Phase 3 | Active not recruiting | BeOne Medicines | 955 | 2020-01-16 | 2026-08-28 |
| Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib Influenza Vaccine - B-cell Malignancies | Terminated | Gilead Sciences | 2 | 2018-10-23 | 2020-02-20 | |
| Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies Low dose ET019002- T Cells, Middle dose ET019002- T Cells, High dose ET019002- T Cells - B-Cell Malignancies | Early Phase 1 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 18 | 2018-08-19 | 2018-08-23 |
| A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Parsaclisib, Itacitinib, Rituximab - B-Cell Malignancies | Phase 1 / Phase 2 | Completed | Incyte Corporation | 88 | 2016-09-22 | 2023-09-28 |
| Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Tirabrutinib, Idelalisib, Entospletinib - B-cell Malignancies | Phase 1 | Terminated | Gilead Sciences | 203 | 2015-06-16 | 2025-06-17 |
| A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Nivolumab, Epacadostat, Chemotherapy - B-cell Malignancies, Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Completed | Incyte Corporation | 307 | 2014-11-26 | 2025-08-14 |
Showing 20 of 24. Sign in to see all of them.
Leukemia, B-Cell (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Colorectal Neoplasms (1) · Glioblastoma (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Hematologic Diseases (5) · Leukemia (4) · Leukemia, Lymphoid (4) · Lymphoma (4) · Lymphoma, Non-Hodgkin (3) · Chronic Disease (2) · Disease Attributes (2) · Lymphoma, B-Cell (2)
zanubrutinib (4) · Rituximab (3) · itacitinib (3) · INCB039110 (2) · parsaclisib (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Carboplatin (1) · Clarithromycin (1) · Diltiazem (1) · Drug Therapy (1) · Etoposide (1) · Fluconazole (1) · Ifosfamide (1) · Influenza Vaccines (1) · Nivolumab (1)
Incyte Corporation (4) · BeOne Medicines (3) · BeiGene (2) · Gilead Sciences (2) · Shenzhen Geno-Immune Medical Institute (2) · TransThera Sciences (Nanjing), Inc. (2) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1) · Assiut University (1) · AstraZeneca (1) · Bristol-Myers Squibb (1) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1) · Curis, Inc. (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · MedImmune LLC (1) · Xinqiao Hospital of Chongqing (1)
United States (12) · China (8) · Italy (6) · Spain (6) · United Kingdom (5) · Australia (4) · France (4) · Czechia (3) · Japan (3) · South Korea (3) · Belgium (2) · Canada (2) · Denmark (2) · Germany (2) · New Zealand (2)
Claudia Corrado, M.D. (1) · Lance Leopold (1) · Li Jianyong (1) · Lung-Ji Chang (1) · Lung-Ji Chang, PhD (1) · Nitin Jain, MD (1) · Peter Langmuir, MD (1) · Qiu Lugui, Ph.D (1) · Xu Wei (1)
PMID 30444200, PMID 38502198, PMID 28178345, PMID 29695516, PMID 30803990, PMID 34152395, PMID 35390135, PMID 35776199, PMID 35900694, PMID 36480811, PMID 38775302, PMID 39563886, PMID 40924923
2016 (2), 2009 (1), 2015 (1), 2017 (1), 2019 (1), 2025 (1)